Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities research analysts at B. Riley reduced their FY2017 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a report issued on Wednesday. B. Riley analyst M. Kumar now forecasts that the biopharmaceutical company will post earnings per share of ($5.07) for the year, down from their previous forecast of ($4.60). B. Riley currently has a “Buy” rating and a $220.00 target price on the stock. B. Riley also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.35) EPS, Q2 2018 earnings at ($1.50) EPS, Q3 2018 earnings at ($1.24) EPS, Q4 2018 earnings at ($1.41) EPS, FY2018 earnings at ($5.20) EPS, FY2019 earnings at ($5.37) EPS, FY2020 earnings at ($2.18) EPS and FY2021 earnings at $6.41 EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. During the same quarter in the prior year, the company earned ($1.21) earnings per share. The company’s quarterly revenue was up 24.8% on a year-over-year basis. TRADEMARK VIOLATION WARNING: “FY2017 Earnings Estimate for Alnylam Pharmaceuticals, Inc. Issued By B. Riley (ALNY)” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/12/fy2017-earnings-estimate-for-alnylam-pharmaceuticals-inc-issued-by-b-riley-alny.html.
Several other brokerages have also recently weighed in on ALNY. Goldman Sachs Group, Inc. (The) upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $62.00 to $163.00 in a research report on Monday, October 2nd. Jefferies Group LLC set a $102.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Barclays PLC upped their price objective on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 10th. BMO Capital Markets restated an “outperform” rating and issued a $99.00 price objective (down from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Finally, Leerink Swann restated a “market perform” rating and issued a $72.00 price objective (down from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $114.57.
Shares of Alnylam Pharmaceuticals (ALNY) opened at $139.98 on Friday. Alnylam Pharmaceuticals has a 52-week low of $35.98 and a 52-week high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.84 and a current ratio of 9.83.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the sale, the president now owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Barry E. Greene sold 85,316 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 215,797 shares of company stock worth $25,035,072. Insiders own 4.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. BlackRock Inc. increased its position in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after purchasing an additional 4,732,617 shares during the last quarter. FMR LLC increased its position in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after purchasing an additional 815,270 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after purchasing an additional 759,295 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $53,226,000. Finally, TIAA CREF Investment Management LLC boosted its holdings in Alnylam Pharmaceuticals by 305.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 508,852 shares of the biopharmaceutical company’s stock valued at $40,586,000 after acquiring an additional 383,214 shares during the period. 94.20% of the stock is currently owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.